BioAtla, Inc. BCAB 深 滬
已收盤 07-25 16:00:00 美东时间
0.3548
-0.022
-5.89%
華盛通- 最 高0.379
- 今 開0.377
- 成交量 158.88万股
- 最 低 0.3499
- 昨 收 0.377
- 總市值 2072.67万
- 52周最高 2.525
- 市盈率 靜 --
- 換手率 2.72%
- 52周最低 0.24
- 委 比 -76.47%
- 總股本 5841.81万
- 歷史最高 76.63
- 量 比 1.43
- 振 幅 7.72%
- 歷史最低 0.24
- 每 手 1
- 風險率 0.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
BioAtla, Inc., a global clinical-stage biotechnology company, announced an oral presentation at the 2025 ESMO TAT Asia Meeting in Hong Kong. The presentation, titled "First-in-human phase I study of a dual-Conditionally Active Biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma," will be presented by Jennifer B. Brooke Valerin on July 18, 2025, at 15:59‒16:06 GMT+8. T...
07-17 12:00
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
BioAtla's BA3182, a dual-CAB EpCAM x CD3 bispecific T-cell engager, showed preliminary success in phase 1 trials for heavily pretreated metastatic adenocarcinoma patients. Safety profile was favorable with low-grade, transient adverse events. Tumor reductions were observed, and dose escalation continues at 1.2 mg weekly. Phase 1 data updates are expected in 2H2025.
07-03 12:00
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
<p>BioAtla announced positive results from a Phase 2 trial of Ozuriftamab Vedotin (Oz-V) in heavily pretreated HPV+ OPSCC patients. The study showed an overall response rate (ORR) of 45% and a disease control rate (DCR) of 100%. Patients had a median of 3 prior lines of therapy, with all failing anti–PD-1 therapy and 85% failing platinum therapy. The oral abstract highlights significant antitumor activity compared to the current standard of care,...
06-02 12:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Longevity Health Holdings (NASDAQ:XAGE) shares moved upwards by 55.5% ...
05-22 05:06
BioAtla shares are trading higher after the company reported better-than-expected Q1 financial results.
BioAtla shares are trading higher after the company reported better-than-expect...
05-07 20:53
BioAtla, Inc. Reports Q1 2025 Financial Results
Bioatla, Inc. ( ($BCAB) ) has released its Q1 earnings. Here is a breakdown of ...
05-07 12:23
BioAtla's Phase 2 Trial Of Ozuriftamab Vedotin Selected For Poster Presentation at 2025 ASCO
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the
04-23 22:09
美股大行评级 | 潜在涨幅778.38%！HC Wainwright & Co.上调BioLine Rx目标价至26美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1113752959213998081.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BioLine Rx(BLRX)"买入"评级，目标价从9美元升至26美元</p> <p>• 德银：上调固特异轮胎橡胶(GT)评级至"买入"，目标价13美元</p> <p
04-01 09:48
HC Wainwright & Co. Reiterates Neutral on BioAtlato Neutral
HC Wainwright & Co. analyst Arthur He reiterates BioAtla (NASDAQ:BCAB) from Neutral to Neutral.
03-31 18:50
BioAtla announces 30% workforce reduction
BioAtla (NASDAQ:BCAB) announced a workforce reduction of ~30%. The total cash payments related to this workforce reduction are estimated to be between $0.5M and $0.6M related to employee severance and...
03-28 05:12
